Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK),
and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days
in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.